Form 4 for BIIB Biogen
Accepted 2023-02-14 00:00:00 ET · period of report 2023-02-10 · accession 0001127602-23-005267 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-14 | 2023-02-10 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | +1,211 | 3,863 | +46% | $0 |
| D | 2023-02-14 | 2023-02-10 | BIIB | Singhal Priya | Head of Development | F - Tax | $286.30 | -372 | 3,491 | -10% | -$106.5K |
| D | 2023-02-14 | 2023-02-10 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | -1,211 | 2,424 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-10 | M | A | 1,211 | $0.00 | 3,863.39 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-10 | F | D | 372 | $286.30 | 3,491.39 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2023-02-10 | M | D | 1,211 | $0.00 | 2,424 | D | $0.00 · — to 2025-02-10 | 1,211 Common Stock | (F1) This award was granted to the reporting person on February 10, 2022 and will vest in three equal installments on each anniversary of the grant date. |